Related Experiment Video

Updated: Mar 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer

Fang Liang1, Qiao Li1, Xiayu Li2

  • 1Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Cancer Research Institute, Central South University, Changsha, Hunan, P.R. China.

International Journal of Oncology
|August 31, 2016
PubMed

Insights

Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) suppresses tumor growth in colorectal cancer. It interacts with pyruvate kinase M2 (PKM2), reducing nuclear PKM2 and cyclin D1 levels.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) was identified as a novel cancer-associated gene.
  • The specific role of TSC22D2 in tumor development, particularly in colorectal cancer (CRC), was previously unknown.

Purpose of the Study:

  • To investigate the function of TSC22D2 in colorectal cancer.
  • To identify proteins that interact with TSC22D2 and elucidate its mechanism of action in tumor suppression.

Main Methods:

  • Quantitative analysis of TSC22D2 expression in colorectal cancer tissues.
  • Co-immunoprecipitation (co-IP) assay combined with mass spectrometry to identify TSC22D2-interacting proteins.
  • Immunoprecipitation and immunofluorescence assays to confirm protein interactions.
  • Assessment of cell growth and molecular changes (nuclear PKM2, cyclin D1) upon TSC22D2 overexpression.

Main Results:

  • TSC22D2 was significantly downregulated in colorectal cancer.
  • Overexpression of TSC22D2 inhibited colorectal cancer cell growth.
  • TSC22D2 was found to interact with pyruvate kinase isoform M2 (PKM2).
  • TSC22D2 overexpression led to reduced nuclear PKM2 levels and suppressed cyclin D1 expression.

Conclusions:

  • TSC22D2 exhibits a tumor suppressor function in colorectal cancer.
  • This function is, at least partially, mediated by the TSC22D2-PKM2-cyclin D1 regulatory axis.
  • The findings provide insights into the role of TSC22D2 in cancer and suggest avenues for future research.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells06:38

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

Published on: January 22, 2021

7.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K